VectivBio (NASDAQ:VECT) is a clinical‐stage biotechnology company dedicated to developing therapies for rare endocrine and metabolic diseases. Its lead product candidate, vekinazero™ (formerly VRS‐317), is designed to address pediatric growth hormone insensitivity and severe short stature. Using proprietary protein engineering technology, VectivBio aims to extend half‐life and enhance receptor binding of therapeutic proteins, potentially reducing dosing frequency and improving patient compliance.
Since its founding in 2019 as a spin‐out from Roche, VectivBio has leveraged an experienced research and development team to build a pipeline targeting the root causes of endocrine disorders. In addition to vekinazero™, the company is advancing several preclinical programs focused on enzyme replacement and metabolic modulation. VectivBio’s platform applies a modular fusion technology that can be adapted to various hormones and enzymes, offering the potential to address a broad range of rare conditions.
Headquartered in Cambridge, Massachusetts, with research operations in Basel, Switzerland, VectivBio conducts clinical trials across North America and Europe. The company collaborates with leading academic centers and patient advocacy groups to accelerate study enrollment and foster partnerships for future commercialization. Through these global alliances, VectivBio seeks to establish itself as a leader in the rare disease space while ensuring access to therapies for underserved patient populations.
Leadership at VectivBio is guided by CEO Hans Schouwink, who brings over two decades of experience in pharma development and commercialization, alongside a management team with deep expertise in protein engineering, clinical operations, and regulatory affairs. Supported by an independent board of directors and scientific advisory committee, the company remains focused on translating its innovative platform into life‐changing treatments for patients with rare endocrine disorders.
AI Generated. May Contain Errors.
